<DOC>
	<DOCNO>NCT01424124</DOCNO>
	<brief_summary>The main objective evaluate safety/tolerability efficacy YHD001 compare singulair placebo patient ( n=96 ) partially control asthma . The study conduct 4 comparative group orally treat YHD001 dose level 1 ( t.i.d . ) , YHD001 dose level 2 ( t.i.d . ) , singulair 10mg ( q.d . ) Placebo 8 week .</brief_summary>
	<brief_title>Safety Efficacy YHD001 Asthma</brief_title>
	<detailed_description>Singulair : Montelukast sodium ( leukotriene modulator )</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Provision sign write informed consent Acceptable medical history , physical exam , laboratory test EKG , screen Nonsmoking ( longer 1 year ) patient asthma Reversible airway obstruction ( increase FEV1 absolute value 12 % great ) 20 30 minute inhalation bâˆ’agonist FEV1 50 % 85 % predict value ( withhold shortacting , inhale b2adrenergic agonist 6 hour ) History clinically significant disease History drug/chemical/alcohol abuse Active upper respiratory tract infection within 3 week , emergency room treatment asthma within 1 month , hospitalization asthma within 3 month prestudy visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>